ido believ epacadostat look like placebo
pt
share sinc initi coverag
compar nbi period today
updat termin epacadostat fail show
os benefit combin keytruda vs keytruda alon remov
epacadostat model compani plan conduct subgroup analys
look variou biomark express tumor
mutat burden may provid addit insight see reason
time continu develop epacadostat consid highli unlik
demonstr efficaci tumor type and/or combin anoth
import binari event horizon remain cautiou
epacadostat provid benefit hr
os hr lean numer wrong direct
hr find rel larg trial
provid first ever glimps control clinic studi strongli suggest
epacadostat efficaci opinion
manag point variou subgroup analys believ could
lead protocol modif clinic trial epacadostat variou
combin tumor type besid eight
studi epacadostat list ct gov believ like outcom could
termin mani studi expect updat call
remov epacadostat model decreas risk-adjust
revenu estim lower dcf-base pt
near term remov epacadostat launch-rel sg
expens chang result revenu ep updat
model detail insid
epacadostat potenti largest unencumb asset pipelin
epacadostat essenti pictur see reason increas
probabl acquisit fact view acquisit less
like unclear us potenti acquir would want get
tangl alreadi partner asset
anoth signific binari event loom horizon olumi
fda advisori panel expect fda brief document focu
rate thrombot event base uncertainti around binari event
remain cautiou share maintain perform rate
biopharma compani
focus small molecul oncolog
jakafi
analyst certif import disclosur see disclosur
develop epacadostat discontinu
regulatori approv launch baricitinib
differenti baricitinib label xeljanz tofacitinib
greater expect advanc pipelin asset
inhibitor signific potenti myelofibrosi mf
polycythemia vera pv potenti indic
clinic investig partner candid baricitinib oral
therapi ra face signific us regulatori delay may
drive revenu upsid eventu deep
driven take-over specul lead valuat premium
fair market valuat view
april brief document post fda advisori
committe meet olumi
april fda advisori committe meet olumi
result jakafi acut gvhd
approv olumi ra us
pipelin asset fail differenti offer strateg advantag
collabor
price target per share base dcf valuat methodolog employ wacc termin growth rate
view appropri compani commerci asset clinical-stag pipelin estim jakafi sale could peak
us includ peak royalti ex-u sale see iclusig olumi smaller contributor revenu
key known downsid risk price target clinic develop risk regulatori risk pipelin addit risk come
build commerci infrastructur indic higher anticip competit drug develop
upsid risk includ acquisit signific premium better expect clinic data drug pipelin
exhibit hypothet part sotp valuat ido remov use price
exhibit dcf show use pt valuat methodolog
drug/indicationexpect launchpeak sale estim mm estimate probabl successnpv mm p-adj npv mm p-adj valu sharejakafi pipelin equiti share outstand use valuat oppenheim co discount analysisoppenheim co except per-shar data revenu chang work work capit thru upequ valu growth valu oppenheim co estimatestermin valu growth rateequ valu per sharetermin valu growth rate
thousand except per share
product royalti revenu olumi eu
jakafi essenti thrombocythemia et
jakafi gvhd
probabl success
probabl success
probabl success
epacadostat tumor sale
probabl success
probabl success
rest pipelin
probabl success
mileston contract research
licens royalti
cost expens
good sold royalti jakafi
good sold amortizatin iclusig right eu
good sold small mol
good sold biolog
amort acquir product right
research develop
adjust research develop non-gaap
up-front consider collabor
share-bas compens
share-bas compens expens
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
share-bas compens sg expens
incom loss oper
incom expens
interest incom expens net
loss debt repurchas
unreal gain long term invest
ep basic dilut
ep non-gaap basic dilut
share use comput ep basic
share use comput ep dilut
fulli dilut share out use valuat
